StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.63+0.23 (+16.43%)

Close on Nov 17, 2026Market cap $168.54MP/E –Yield –

Earnings

Inovio Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$298.90K
Adjusted EPS, Q3 FY2026
-$0.50
-$0.87 a year earlier
Latest guidance
Issued
Nov 10, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Inovio Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close$298.90K–-$0.50–Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close––-$0.07–Release
Q1 FY2026ended Mar 31, 2026May 13, 2026after the close––-$0.28–Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close––-$0.26–Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025after the close––-$0.87–Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close––-$0.61–Release
Q1 FY2025ended Mar 31, 2025May 13, 2025after the close––-$0.51–Release
Q4 FY2024ended Dec 31, 2024Mar 18, 2025after the close––-$0.65–Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024after the close––-$0.89–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$100.76K-55.4%-$1.19–Release
Q1 FY2024ended Mar 31, 2024May 13, 2024after the close––-$1.31–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Inovio Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
operational net cash burnQ4 FY2026$21.00M–NewNov 10, 2026

Guidance history

Every forecast Inovio Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026operational net cash burnQ4 FY2026$21.00MNew
Aug 12, 2026operational net cash burnQ3 FY2026$18.00MNew
Mar 12, 2026operational net cash burnQ1 FY2026$22.00MNew
Aug 12, 2025operational net cash burnQ3 FY2025$22.00MNew
May 13, 2025operational net cash burn estimateQ2 FY2025$22.00MNew
Mar 18, 2025operational net cash burnQ1 FY2025$27.00MNew
Nov 14, 2024operational net cash burnQ4 FY2024$24.00MNew
Aug 8, 2024operational net cash burnQ3 FY2024$28.00MNew
May 13, 2024operational net cash burnQ2 FY2024$30.00MNew
Nov 9, 2023cash burn estimateQ4 FY2023$26.00MNew
Aug 9, 2023cash burnQ3 FY2023$34.00MNew
May 10, 2023cash burnQ2 FY2023$33.00MNew
Mar 1, 2023cash burn estimateQ1 FY2023$32.00MNew
Nov 8, 2022cash burnQ4 FY2022$45.00MNew
Aug 9, 2022cash burnQ3 FY2022$73.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Inovio Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Update
  6. Results
  7. News
  8. News
  9. Results
  10. News
  11. News
  12. Results
  13. Update
  14. News
  15. News

See a number that looks wrong?